Exploring new antiviral strategies by studying viral protein modifications
Defining the viral PTMome: Towards the development of novel antiviral approaches
['FUNDING_OTHER'] · CLEVELAND CLINIC LERNER COM-CWRU · NIH-10894186
This study is looking at how certain viruses, like HIV, change their proteins after they're made, and by learning more about this process, researchers hope to find new ways to create treatments that can better fight these viruses and work even when they change.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CLEVELAND CLINIC LERNER COM-CWRU (nih funded) |
| Locations | 1 site (CLEVELAND, UNITED STATES) |
| Trial ID | NIH-10894186 on ClinicalTrials.gov |
What this research studies
This research investigates how viral proteins, particularly those from HIV and other rapidly mutating viruses, are modified after they are created. By understanding these modifications, the research aims to identify new ways to disrupt the virus's ability to replicate and evade treatment. The approach focuses on the role of human enzymes that interact with viral proteins, which could lead to innovative antiviral therapies that are less likely to be affected by viral mutations. Patients may benefit from new treatments that are effective against a broader range of viral infections.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living with HIV or other viral infections that are difficult to treat due to resistance.
Not a fit: Patients with viral infections that do not involve significant mutation or those who are not infected with the targeted viruses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel antiviral therapies that are more effective against resistant viral strains.
How similar studies have performed: Other research has shown promise in targeting viral protein modifications, indicating that this approach could lead to significant advancements in antiviral therapies.
Where this research is happening
CLEVELAND, UNITED STATES
- CLEVELAND CLINIC LERNER COM-CWRU — CLEVELAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GACK, MICHAELA ULRIKE — CLEVELAND CLINIC LERNER COM-CWRU
- Study coordinator: GACK, MICHAELA ULRIKE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus, Communicable Diseases